Madrigal Announces Additional Positive Results from the Pivotal Phase III MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. announced additional results from the pivotal Phase III MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist.